Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2021-04-20 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2020年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2020 Annual Report Summary" of 葵花药业集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2020, including revenue, net profit, quarterly financial data, shareholder information, business overview, accounting policy changes, and management discussion. The presence of comprehensive financial statements and analysis for the full fiscal year confirms it is an Annual Report. The document length (10,110 characters) and content depth support that this is the report itself, not just an announcement or summary notice. Therefore, the appropriate classification is Annual Report (10-K). FY 2020
2021-04-20 Chinese
北京市天元律师事务所关于葵花药业集团股份有限公司2021年员工持股计划的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the company's 2021 employee stock ownership plan (员工持股计划). It extensively discusses the legal compliance, procedures, and regulatory requirements related to the employee stock ownership plan, including references to relevant laws, regulatory guidelines, and company resolutions. The document is not a financial report, earnings release, or management discussion but a legal opinion on a specific corporate action. It is not an announcement of a report but a standalone legal opinion document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal opinion related to a corporate governance matter and does not fit other more specific categories like MANG or CAP. The document length (7839 characters) and content confirm it is a substantive legal opinion rather than a brief announcement or certification.
2021-04-12 Chinese
独立董事关于公司第四届董事会第五次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's fourth board meeting, specifically regarding the 2021 employee stock ownership plan. It references compliance with laws and regulations, the board's review process, and the submission of the plan to the shareholders' meeting. The document is a formal opinion or statement from independent directors rather than a full report or financial statement. It does not contain financial data or results, nor is it an announcement of voting results or a proxy solicitation. It fits best under Regulatory Filings (RNS) as a formal regulatory disclosure that does not fit other specific categories.
2021-04-05 Chinese
董事会关于公司2021年员工持股计划（草案）是否符合《关于上市公司实施员工持股计划试点的指导意见》相关规定的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors regarding the company's 2021 employee stock ownership plan (ESOP) draft and its compliance with relevant regulatory guidelines and laws. It discusses the legality, compliance, and procedural correctness of the ESOP but does not contain financial statements or detailed financial data. It is not an announcement of voting results, nor a full report or presentation. The document is a regulatory compliance statement related to employee stock plans, which fits best under Regulatory Filings (RNS) as it does not meet criteria for other specific categories like Share Issue/Capital Change (SHA) or Proxy Solicitation (PSI). The document length is short and focused on compliance explanation rather than financial or capital changes.
2021-04-05 Chinese
2021年员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of an employee stock ownership plan (员工持股计划) for the year 2021 by 葵花药业集团股份有限公司. It includes extensive information about the plan's participants, stock sources, funding, pricing, lock-up periods, management structure, voting rights, and other operational details. The document references relevant laws and regulations, and it is a comprehensive plan draft rather than a brief announcement or a simple notice. It is not a financial report like an annual or interim report, nor is it a call transcript or a legal proceeding update. It is also not a proxy solicitation or voting results announcement. The content is focused on the employee stock ownership plan, which is a form of capital/financing update related to company fundraising and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement of a report, so it is not RPA or RNS.
2021-04-05 Chinese
上海荣正投资咨询股份有限公司关于葵花药业集团股份有限公司2021年员工持股计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the 2021 Employee Stock Ownership Plan (ESOP) draft of Kuaihua Pharmaceutical Group Co., Ltd. It is a detailed report prepared by an independent financial advisor, covering the plan's principles, participants, scale, stock sources, funding, pricing, duration, lock-up periods, management structure, changes, termination, and rights of participants. The content is focused on the employee stock ownership plan, its feasibility, compliance with laws and regulations, and impact on shareholders. This type of document is a standalone advisory report related to a capital/financing activity (employee stock ownership plan) rather than a full annual or interim financial report. It is not a regulatory announcement or a brief notice but a comprehensive advisory report on a financing-related plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-04-05 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.